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28 Abstract 
 
29 Chronic Hepatitis B virus (HBV) infection is a leading cause of liver disease worldwide. Virus- 
 
30 induced diseases include cirrhosis, liver failure and hepatocellular carcinoma. Current 
 
31 therapeutic strategies may at best control infection without reaching cure. Complementary 
 
32 antiviral strategies aimed at viral cure, are therefore urgently needed. HBV entry is the first 
 
33 step of the infection cycle, which leads to the formation of cccDNA and the establishment of 
 
34 chronic infection. Viral entry may thus represent an attractive target for antiviral therapy. This 
 
35 review  summarizes  the  molecular  virology  and  cell  biology  of  HBV  entry,  including the 
 
36 discovery and development of new HBV entry inhibitors, and discusses their potential in 
 
37 future treatment of HBV infection. 
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56 Introduction 
 
57 With 250-350 million affected individuals, chronic hepatitis B virus (HBV) infection is a major 
 
58 public health problem. Chronic HBV infection can lead to advanced liver disease such as 
 
59 liver  cirrhosis  and  liver failure (1-4). Furthermore, HBV infection is a leading cause of 
 
60 hepatocellular cellular carcinoma (HCC) worldwide (1-4). Despite a very efficient protective 
 
61 vaccine, HBV prevalence has only marginally declined. Current antiviral therapies involving 
 
62 pegylated type-I interferon (IFN) and nucleos(t)ide analogs (NUCs) may at best control viral 
 
63 infection. There is no anti-HBV treatment available for efficient viral clearance in HBV 
 
64 carriers. HBV is a small, enveloped DNA virus of the Hepadnaviridae family, which 
 
65 exclusively infects human hepatocytes (4). The viral coat consists of three envelope proteins: 
 
66 small S (S), middle M (S + preS2 region) and large L (S + preS2 region + preS1 region) (5). 
 
67 Unique features of the HBV life cycle include a genome replication mechanism that uses a 
 
68 reverse transcription step (targeted by NUCs) to convert pregenomic RNA to genomic DNA, 
 
69 and the formation of  a covalently closed  circular DNA (cccDNA)  in  the nucleus  of  infected 
 
70 hepatocytes, the equivalent of proviral DNA in retrovirus-infected cells (6). The HBV cccDNA 
 
71 functions as a minichromosome in the nucleus of infected cells to serve as a template for 
 
72 transcription into viral mRNAs. Because it is responsible for viral persistence, HBV cccDNA 
 
73 is the target of choice for elimination of infection (6). HBV infection in humans may become 
 
74 more complex when patients are co-infected with the hepatitis delta virus (HDV). HDV is a 
 
75 subviral infectious agent, and an obligate satellite of HBV, which uses the HBV envelope 
 
76 proteins to assemble infectious particles and thereby propagate with the helper HBV. As for 
 
77 HBV, there is no curative treatment available (7), and chronic HBV/HDV co-infections lead to 
 
78 increased liver damage and HCC risk as compared to HBV mono-infections (8). 
 
79 As current treatments may control, but not cure infection, new therapeutic strategies 
 
80 are needed, especially for treatment of chronic infections. Novel therapeutic approaches 
 
81 include host-targeting compounds that inhibit virus-host interactions as reviewed previously 
 
82 (9). As the first step of infection necessary for the formation of cccDNA and the 
 
83 establishment of chronic infection, viral entry represents an antiviral target in complement of 
84 current therapies (9-11). As HDV and HBV share the same envelope and entry pathway, 
 
85 targeting viral entry is of particular interest for the treatment of HBV/HDV co-infection. Here, 
 
86 we review the recent developments in our understanding of the HBV/HDV entry process, 
 
87 including the consequent new antiviral strategies. 
 
88 
 
89 HBV entry: the quest for a viral receptor 
 
90 Although the HBV DNA replication cycle has been described in detail, molecular interactions 
 
91 between virus and host factors are not fully understood. One reason for this limitation has 
 
92 been the lack of robust cell culture infection systems for the study of the full life cycle. Viral 
 
93 entry can be observed in primary cultures of human hepatocytes (PHH) and Tupaia belangeri 
 
94 (PTH)  hepatocytes  (12,  13).  One human hepatic  progenitor  cell  line  (HepaRG)  has also 
 
95 demonstrated susceptibility to HBV infection following DMSO-mediated differentiation, and it 
 
96 has been used extensively in recent years for HBV and HDV in vitro infection assays (14). 
 
97 However, HBV/HDV susceptible systems are limited by a number of constraints: 
 
98 susceptibility to infection is highly dependent on culture conditions and, in the case of PHH, 
 
99 subject to donor-to-donor variability (4, 10, 15). Besides viral entry, all other steps of the HBV 
 
100 or HDV replication cycles have been studied for many years in permissive hepatoma cell 
 
101 lines, such as Huh7 and HepG2 cells (15-18). These cell lines, however, are not susceptible 
 
102 to HBV and HDV infection, limiting their use to genome replication, transcription, translation, 
 
103 viral assembly and release, but not viral entry (19). Consequently, the HBV receptor(s) have 
 
104 remained unknown for many years (20, 21). Only in late 2012 was a first bona-fide HBV 
 
105 receptor identified at the basolateral membrane of differentiated human hepatocytes. Using 
 
106 PTH as target cells, and a labeled preS1 peptide as a bait to substitute for HBV envelope 
 
107 proteins, Yan et al. (22) identified the sodium taurocholate co-transporting polypeptide 
 
108 (NTCP), a bile-acid transporter mainly expressed at the basolateral membrane of 
 
109 hepatocytes (23) encoded by the SLC10A1 gene, as an HBV-specific receptor (22, 24). In 
 
110 parallel, Ni et al. (24) had compared the transcriptomic pattern of differentiated (HBV 
 
111 susceptible) HepaRG cells to that of undifferentiated (not susceptible) HepaRG cells, and 
112 found that NTCP mRNA was expressed upon differentiation. Interestingly, the 
 
113 overexpression of human NTCP in permissive hepatoma cells such as Huh7 and HepG2 
 
114 cells that lack endogenous expression of NTCP, conferred susceptibility to both HDV and 
 
115 HBV infection, thereby providing a cell culture model for the study of the entire HBV life 
 
116 cycle, including viral entry (22, 24). 
 
117 
 
118 Molecular biology of HBV entry 
 
119 The interaction between HBV or HDV virions and hepatocytes begins with attachment to cell 
 
120 surface heparan sulfate proteoglycans (HSPGs) (25) (Figure 1). HSPGs are glycoproteins 
 
121 that play major roles in development and physiology (26), but they are also used for cellular 
 
122 attachment of numerous pathogens, including viruses (27). In the case of HBV, HSPG 
 
123 binding function was demonstrated by the ability of soluble heparin and other sulfated 
 
124 polysaccharides to impair infectivity of HDV and HBV virions (28, 29). Moreover, heparinase 
 
125 treatment of susceptible cells could inhibit HDV and HBV infection (28, 30). Using HepaRG 
 
126 cells, and a heparin-binding assay, Sureau and Salisse (30) reported that HSPGs bind to the 
 
127 antigenic loop of the HBV envelope protein S domain. HBV-HSPG interaction is one 
 
128 explanation to the highly specific tissue tropism of the virus, as viral glycoproteins recognize 
 
129 specific patterns of hepatic proteoglycans (including the degree of sulfation of HSPG) (25, 
 
130 29). Taking advantage of NTCP-based cell culture systems and using a siRNA library 
 
131 targeting all members of HSPG families, Verrier et al. (31) recently demonstrated that 
 
132 glypican 5 (GPC5) was an attachment factor for HDV and HBV at the cell surface of 
 
133 hepatocytes. The involvement of GPC5 in HBV binding was confirmed by the inhibitory effect 
 
134 of an anti-GPC5 monoclonal antibody and by the ability of soluble recombinant GPC5 protein 
 
135 to neutralize HBV in vitro infection (31). GPC5 is a member of the glypican family, consisting 
 
136 of extracellular HSPGs bound at the cell surface through a glycosyl-phosphatidylinositol 
 
137 anchor (32). GPC5 carries five insertion sites (compared to three for GPC3, for instance) for 
 
138 highly sulfated glycosaminoglycan chains (33) and is expressed in PHH (31), possibly 
 
139 explaining the specific affinity of GPC5 for HBV virions. Since HSPG, and particularly GPC5, 
140 are involved in many cellular processes, including the control of cell division, growth 
 
141 regulation, FGF2- or Hedgehog signaling, HBV-HPSG interactions may also play a role in the 
 
142 pathogenesis of virus-induced liver disease (26, 33, 34). Further studies are needed for a 
 
143 comprehensive overview of HSPG-HBV interactions. 
 
144 Following initial attachment to HSPGs, HBV and HDV virions bind to NTCP (Figure 
 
145 1). Being a liver-specific transporter, NTCP is likely to play the major role in HBV liver tropism 
 
146 (35).  In  the liver,  NTCP is  responsible  for the  transport  of  conjugated bile  salts, typically 
 
147 taurocholate (36). The preS1 domain at the surface of HBV virions directly interacts with the 
 
148 bile acid pocket site (aa 157–165) of NTCP (22, 24). The overlap between NTCP HBV 
 
149 receptor function and NTCP bile acid transporter function was confirmed by the ability of 
 
150 NTCP S267F mutation to disrupt not only bile acid transport but also HDV and HBV infection 
 
151 in a cell culture model (37). Interestingly, two genetic studies showed that the S267F 
 
152 SLC10A1 allele was associated with resistance to chronic HBV infection (38) and with 
 
153 decreased risk of cirrhosis and HCC in HBV carriers (39). However, the observation that 
 
154 S267F homozygous patients can still be infected by HBV (38, 39) demonstrates that this 
 
155 mutation does not totally suppress HBV entry in vivo, and suggests that other hepatic 
 
156 factor(s) can function as surrogate HBV receptors in absence of functional NTCP. A recent 
 
157 study identified another domain (aa 84–87) within NTCP that plays a crucial role in HBV 
 
158 entry, probably at a postbinding step (40). Interestingly, the overexpression of human NTCP 
 
159 in non-human cells is sufficient to confer susceptibility to HDV infection, suggesting that no 
 
160 additional human-specific factor is required for viral attachment, fusion and trafficking of the 
 
161 HDV genome to the cell nucleus (35, 40). However, hNTCP expression in mouse cells is not 
 
162 sufficient to confer susceptibility to HBV infection. Using fusion between hNTCP- 
 
163 overexpressing mouse cells and permissive non-susceptible HepG2 cells, Lempp et al. (41) 
 
164 recently suggested that the absence of HBV infection was due to a lack a host factor 
 
165 required for HBV replication. Following NTCP binding, HBV virions are thought to be 
 
166 internalized by endocytosis. Both clathrin- (42) and calveolin-dependent (43) processes have 
167 been proposed, but to date, the detailed mechanism of NTCP-mediated internalization 
 
168 remains unclear. 
 
169 Currently, only a limited number of host proteins are known to be involved in HBV 
 
170 entry, and it is expected that the new NTCP-based infection models will allow the discovery 
 
171 of other entry factors. Given the relatively limited percentage of infected cells in this models, 
 
172 despite NTCP overexpression and high multiplicity of infection (22, 24, 31, 44), it is likely that 
 
173 additional factors indeed play an important role at viral entry. 
174 
175 HBV cell entry inhibitors 
 
176 Entry inhibitors have emerged as attractive candidates for prevention and treatment of 
 
177 chronic viral infections (10, 35). Interestingly, in the context of hepatitis C virus (HCV), which 
 
178 also leads to chronic infection of the liver, an entry inhibitor used in monotherapy was shown 
 
179 to cure chronic infection in human liver chimeric mice (45). It is likely that hepatocyte turnover 
 
180 in the absence of de novo infection results in viral clearance (45). Furthermore, broadly 
 
181 neutralizing anti-envelope antibodies have been shown to control and eliminate persistent 
 
182 HCV infection in humanized mouse models (46). Indeed, by blocking reinfection and 
 
183 protecting uninfected hepatocytes from de novo infection, entry inhibitors may open 
 
184 perspectives for novel therapeutic approaches for HBV infection. 
 
185 Neutralizing antibodies targeting viral envelope epitopes were the earliest entry 
 
186 inhibitors explored for HBV. Hepatitis B immunoglobulin (HBIG), a mixture of polyclonal 
 
187 antibodies targeting the HBV S protein, is currently used to prevent liver graft reinfection in 
 
188 HBV-positive patients (47). Monoclonal antibodies directed against the S protein (17.1.41 
 
189 and 19.79.5) were shown to reduce HBV viral load and HBsAg levels in animal models (48) 
 
190 and in patients in a phase I clinical trial (49), but only for several days following treatment. 
 
191 Interestingly, a recent study demonstrated that the administration of a novel monoclonal anti- 
 
192 HBsAg antibody (E6F6) in a mouse model mimicking HBV infection not only suppressed the 
 
193 levels of HBsAg and HBV DNA for several weeks but also facilitated the restoration of anti- 
 
194 HBV T-cell response (50, 51). Other monoclonal antibodies targeting the preS1 domain 
195 demonstrated marked anti-HBV activity in vitro (52) and in animal models (53) but have not 
 
196 been pursued in clinical trials. 
 
197 Targeting host cell entry factors is a novel strategy that has been proposed in the 
 
198 context of HBV infection (10, 35). The attachment of HBV particles to the target hepatocyte 
 
199 relies on low-affinity interactions with HSPGs (25, 29). Small molecules that non-specifically 
 
200 interfere with HSPG binding therefore inhibit HBV infection. Highly sulfated compounds such 
 
201 as heparin (25) and suramin (54) inhibit HBV attachment by competing with cellular HSPGs 
 
202 for the binding sites in HBV surface proteins. GPC5 was recently identified as a HSPG 
 
203 possibly involved in this process (31). Indeed, a monoclonal antibody targeting GPC5 
 
204 inhibited HBV infection in cell culture (31). Furthermore, synthetic anti-lipopolysaccharide 
 
205 peptides (SALPs) that bind to heparan sulfate moieties on the cell surface inhibit infection 
 
206 with a variety of enveloped viruses (55). 
 
207 Since its discovery as a receptor for HBV/HDV, NTCP has been extensively explored 
 
208 as an antiviral target. The molecules targeting NTCP that exhibit antiviral functions against 
 
209 HBV are listed in Table 1. Myrcludex B, a myristoylated preS1-derived peptide, binds to 
 
210 NTCP and inhibits HBV infection by blocking binding of HBV to its receptor (10). PreS1- 
 
211 derived peptides inhibit HBV/HDV infection in vivo (56), and Myrcludex B prevents HBV 
 
212 spread in human liver chimeric mice (57). It is currently being evaluated in a phase IIa clinical 
 
213 trial (58). The first data suggest that Myrcludex B is well tolerated. The inhibition of HBV entry 
 
214 seems to be correlated with a decrease in both HBV DNA (> 1 log10) and HDV RNA, and 
 
215 with an improvement of hepatic parameters (ALT) (58). Other molecules also target NTCP 
 
216 and inhibit HBV infection. Cyclosporin A, a cyclic peptide, interferes with HBV entry as a 
 
217 result of its interactions with NTCP (44, 59). Ezetimibe, a small molecule inhibitor of NTCP- 
 
218 mediated bile acid uptake, also inhibits HBV/HDV entry by apparently similar mechanisms 
 
219 (60). Among several FDA-approved drugs with NTCP-inhibiting activity, irbesartan, a drug 
 
220 used for hypertension treatment, inhibited HBV infection in HepG2-NTCP cells as well as 
 
221 HDV infection in Huh7-NTCP cells (61, 62). Vanitaracin A, a tricyclic polyketide identified 
 
222 from a fungal secondary metabolite library, also interacts with NTCP to inhibit HBV/HDV 
223 infection  (63).  Ritonavir,  an antiretroviral drug  active  against  HIV infection,  and  having a 
 
224 putative inhibitory effect on NTCP metabolic  function  (64)  inhibits  HDV  infection  in  Huh7- 
 
225 NTCP cells (62). A small screen of phytochemicals identified the green tea polyphenol 
 
226 epigallocatechin gallate as another HBV inhibitor, which possibly interferes with HBV uptake 
 
227 by altering the localization and stability of NTCP (65). 
 
228 
 
229 Conclusion and perspectives 
 
230 Chronic HBV infection is a major public health problem worldwide. Since current anti-HBV 
 
231 treatments do not effectively cure infection (i.e., eliminate cccDNA), novel treatment 
 
232 approaches are needed. Entry inhibitors may contribute to cccDNA elimination through 
 
233 inhibition of cccDNA synthesis and prevention of entry in non-infected hepatocytes. However, 
 
234 as viral entry inhibitors including host-targeting compounds do not directly target cccDNA, 
 
235 they should be considered as a complementary antiviral strategy in combination with other 
 
236 antiviral molecules, such as IFNs that can control cccDNA activity (9, 10, 35, 66-68). Recent 
 
237 progress in understanding the HBV entry process, particularly after the discovery of NTCP 
 
238 acting as a receptor, has lead to the identification of novel antiviral compounds for treatment 
 
239 of HBV and HDV infections. A key question will be whether entry inhibitors will help to cure 
 
240 HBV infection by preventing entry into cccDNA-free hepatocytes, while cccDNA-positive 
 
241 hepatocytes are eliminated by liver turnover. Further studies in state-of-the-art animal models 
 
242 and clinical trials are needed to address these questions, to ultimately establish the real 
 
243 place of entry inhibitors in the anti-HBV arsenal. 
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500 Figure legend 
 
501 Figure 1. Molecular mechanisms of HBV entry and entry inhibitors. HBV viral particles 
 
502 first interact with hepatic HSPGs, including GPC5. This interaction is inhibited by a 
 
503 monoclonal anti-GPC5 antibody or heparinase treatment. HBV then binds directly to NTCP at 
 
504 the bile acid pocket site. Several NTCP inhibitors block this interaction and prevent HBV 
 
505 entry,such as cyclosporin A, ezetimibe, irbesartan, vanitaracin A, ritonavir or 
 
506 epigallocatechin gallate. A synthetic HBV-derived preS1 peptide (Myrcludex B) exhibits a 
 
507 strong antiviral activity by competing with HBV for NTCP binding. After binding to NTCP, the 
 
508 virus is internalized but the underlying mechanisms are still unknown. 
 
509 Table legend 
 
510 Table 1. Examples of HBV entry inhibitors targeting NTCP in hepatocytes 
 
Table 
 
Name Class Development stage References 
Myrcludex B Myristoylated lipopeptide Clinical phase II [57] 
Cyclosporin A Immunosuppressant Cell culture [44, 59] 
Ezetimibe b-lactam Cell culture [60] 
Irbesartan Angiotensin receptor blocker Cell culture [61, 62] 
Vanitaracin A Fungal tricyclic polyketide Cell culture [63] 
Ritonavir HIV protease inhibitor Cell culture [62] 
Epigallocatechin gallate Green tea polyphenol Cell culture [65] 
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